JOHNSON & JOHNSON is 85.6x more valuable than Praxis Precision Medicines, Inc. by market capitalization ($574.10 B vs $6.71 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PRAX | JNJ |
|---|---|---|
| Market cap | $6.71 B | $574.10 B |
| US-listed rank | #1183 | #20 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$303.00M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 474 | 984 |
JOHNSON & JOHNSON is 85.6x more valuable than Praxis Precision Medicines, Inc. by market capitalization ($574.10 B vs $6.71 B).
In their latest fiscal years, Praxis Precision Medicines, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Praxis Precision Medicines, Inc. and JOHNSON & JOHNSON, or browse the full rankings.